Kundenlogin- Zusatztext
This volume gives an overview of state of the art technologies and future developments in the field of preclinical pharmaceutical research. A balanced mix of experts from academia and industry give insight in selected new developments in the drug discovery pathway. The topics cover the different parts of the drug discovery process, starting with new developments in the target identification and validation area. The lead generation part as a next step focuses on the requirements and technologies to identify new small molecules as lead compounds for further optimization; in a second section the technologies to identify biologics as leads are addressed. The final part focuses on the pharmacological models and technologies to characterize new compounds and the impact of biomarkers to facilitate the transfer of drug candidates into the development phase.
- Kurztext
In depth insights into drug discovery and early drug developmentLatest technologies of target discovery and lead generationNew approaches to transfer drug candidates to clinical development
- Autorenportrait
Dr. Ulrich Nielsch, Bayer Pharma AG,Wuppertal, GermanyDr. Ulrike Fuhrmann, Bayer Pharma AG, Berlin, GermanyProf. Dr. Stefan Jaroch, Bayer Pharma AG, Berlin, Germany
This volume gives an overview of state of the art technologies and future developments in the field of preclinical pharmaceutical research. A balanced mix of experts from academia and industry give insight in selected new developments in the drug discovery pathway. The topics cover the different parts of the drug discovery process, starting with new developments in the target identification and validation area. The lead generation part as a next step focuses on the requirements and technologies to identify new small molecules as lead compounds for further optimization; in a second section the technologies to identify biologics as leads are addressed. The final part focuses on the pharmacological models and technologies to characterize new compounds and the impact of biomarkers to facilitate the transfer of drug candidates into the development phase.
